FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice.

ABSTRACT:

Background and purpose

The advanced glycation end products (AGEs) participate in the pathogenesis of diabetic nephropathy (DN) by promoting renal inflammation and injury. L-carnosine acts as a quencher of the AGE precursors reactive carbonyl species (RCS), but is rapidly inactivated by carnosinase. In this study, we evaluated the effect of FL-926-16, a carnosinase-resistant and bioavailable carnosine derivative, on the onset and progression of DN in db/db mice.

Experimental approach

Adult male db/db mice and coeval db/m controls were left untreated or treated with FL-926-16 (30 mg·kg^-1 body weight) from weeks 6 to 20 (prevention protocol) or from weeks 20 to 34 (regression protocol).

Key results

In the prevention protocol, FL-926-16 significantly attenuated

SUBMITTER: Iacobini C 

PROVIDER: S-EPMC5740255 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature